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Background: Beta-blockers are frequently withheld in patients with cardiovascular disease 
who also have chronic obstructive pulmonary disease (COPD) because of concerns that they 
might provoke bronchospasm and cause deterioration in health status. Although beta1-selective 
beta-blockers are associated with reduced mortality in COPD patients, their effects on health 
status are unknown. The aim of this study was to investigate the relationship between beta-
blockers and health-related quality of life (HRQOL) in patients with peripheral arterial disease 
and COPD.
Methods: Of the original cohort of 3371 vascular surgery patients, 1310 had COPD of whom 
469 survived during long-term follow-up. These COPD patients were sent the Short Form-36 
(SF-36) health-related quality of life questionnaire, which was completed and returned by 
326 (70%) patients.
Results: No significant differences in any of the SF-36 domains were observed between COPD 
patients who did and did not use beta-blockers (p  0.05 for all). Furthermore, beta-blockers 
were not associated with any impairment in HRQOL among patients with COPD.
Conclusion: Beta-blockers had no material impact on the HRQOL of patients with peripheral 
arterial disease who also had COPD. This suggests that beta-blockers can, in most circumstances, 
be administered to patients with COPD without impairment in HRQOL.
Keywords: beta-blockers, chronic obstructive pulmonary disease, vascular surgery, health-
related quality of life
Introduction
Patients with chronic obstructive pulmonary disease (COPD) often have or develop 
co-existing cardiovascular diseases including congestive heart failure, ischemic heart 
disease and hypertension.1 Beta-blockers are indicated in most of these conditions, 
as they improve heart function, symptoms and survival.2,3 However, there is under-
utilization of beta-blockers in cardiovascular patients with COPD because of concerns 
that these drugs may induce bronchoconstriction and worsen symptoms.4 Although the 
data are mixed, the total evidence suggests that beta1-selective beta-blockers (at least in 
the short term) do not worsen pulmonary function5–10 and are associated with reduced 
mortality in patients with cardiovascular disease who have COPD.11–13 The long-term 
effects on health status and health-related quality of life (HRQOL) of beta-blockers in 
COPD are unknown. On the one hand, beta-blockers may improve HRQOL because 
of their beneficial effects on cardiac performance; on the other hand, beta-blockers 
may cause impaired physical, social and emotional functioning owing to their side 
effects and/or by causing worsening of lung function. The latter may partly explain International Journal of COPD 2009:4 178
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the sub-optimal prescription rate of these drugs for patients 
with COPD. We thus sought to determine the relationship 
between beta-blockers and HRQOL of patients with periph-
eral arterial disease, who also had COPD.
Methods
Patients
The study is based on a subgroup of the original cohort of 
vascular surgery patients, who have been described previ-
ously.13 Briefly, a detailed cardiac history, in addition to 
clinical and demographic characteristics, were obtained in all 
patients undergoing a peripheral vascular operative procedure 
prior to their surgery. Their survival status was ascertained 
at long-term follow-up (up to 10 years) using the municipal 
civil registry. HRQOL of patients was determined at follow-
up using a self-administered questionnaire that was mailed 
to all eligible subjects (see below). In this mailing, we also 
obtained information regarding the use of beta-blockers using 
a short questionnaire.
COPD
The diagnosis of COPD was based on spirometric evidence for 
fixed airflow obstruction as assessed by a post-bronchodilator 
forced expiratory volume in one second (FEV1) to forced vital 
capacity (FVC) ratio of less than 0.70 and FEV1 of 80% 
of predicted, which was obtained at baseline prior to their 
original vascular surgery.14 Patients who did not undergo 
spirometry were categorized as not having COPD if they 
did not complain of cough, dyspnea or sputum production, 
were not taking any pulmonary medication (bronchodilators 
or corticosteroids) and demonstrated normal arterial blood 
gases on room air defined by arterial carbon dioxide tension 
(paCO2)  6.4 kPa and oxygen tension (paO2)  10.0 kPa. 
Patients without spirometry who met any one of these criteria 
were classified as having COPD.
health-related quality of life
For the assessment of HRQOL, the Dutch version of the 
Medical Outcomes Study 36-Item Short Form Health Survey 
(SF-36) was used.15,16 SF-36 is a widely used generic ques-
tionnaire to measure patients’ health status and has been used 
previously in patients with COPD.17–19 The questionnaire 
contains 36 items covering 8 domains: physical function-
ing (PF), role physical (RP), bodily pain (BP), general health 
(GH), vitality (VT), social functioning (SF), role emotional 
(RE) and mental health (MH). The domains scores range from 
0 to 100, with higher scores indicating better HRQOL.
statistical analysis
The primary exposure variable was the use of beta-blockers 
at baseline and the primary endpoint of the present study was 
HRQOL at follow-up. The baseline categorical variables of 
the patients who did and did not use a beta-blocker were 
compared using a chi-square test for dichotomous variables 
and a Student’s t-test for continuous variables. Dichotomous 
variables are presented as percentages, while continuous 
variables are presented as mean ± standard deviation (SD). 
The domains of the SF-36 were converted into tertiles for 
parsimony and subsequently dichotomized,20,21 with the 
lowest tertile indicating worst health status and the highest 
two tertiles representing best health status. Univariate and 
multivariate logistic regression analyses were used to deter-
mine the association between beta-blocker use and health 
status. In the multivariate analysis, adjustments were made 
for all baseline characteristics that might reasonably affect 
HRQOL including age, gender, diabetes mellitus, hyper-
tension, hypercholesterolemia, renal dysfunction, current 
smoking, obesity, type of surgery (abdominal aortic surgery 
[AAA], carotid endarterectomy [CEA], or lower limb arterial 
reconstruction procedures [LLR]), year of surgery, previous 
ischemic heart disease (myocardial infarction, coronary artery 
bypass graft, percutaneous coronary intervention or angina 
pectoris), heart failure, cerebrovascular event (CVA) or tran-
sient ischemic attack (TIA), statins, aspirin, corticosteroids 
and bronchodilators. To correct for the differential follow-up, 
adjustments were made for the number of follow-up years. 
Additionally, a propensity score was added as a covariate 
to the model to adjust for the likelihood of receiving beta-
blockers. This propensity model contained all variables which 
were included in the logistic regression analysis, except for 
the number of follow-up years. Odds ratios (OR) are presented 
as risk estimates with 95% confidence intervals (CI). For all 
tests, a 2-sided p-value of 0.05 was considered significant. 
All tests were performed using SPSS 15.0 for Windows.
Results
Patients
In total, 1310 (39%) of the original 3371 patients had COPD. 
Of these patients, two had moved abroad, 28 were lost to 
follow-up and 469 (36%) survived during the follow-up 
period. The median follow-up time was 6.4 years with an 
interquartile range of 2.9 to 9.3 years. All 469 patients were 
sent the SF-36 questionnaire at follow-up, which was com-
pleted and returned by 326 (70%) patients. An overview of 
the patient inclusion for this study is presented in Figure 1.International Journal of COPD 2009:4 179
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Clinical baseline characteristics are presented in Table 1. 
Of the 326 patients with peripheral arterial disease and COPD, 
59% (n = 191) received beta-blockers. The mean age was 
66 ± 10 years and 80% (n = 262) were men. Patients on 
beta-blockers were older and were more likely to have had a 
previous myocardial infarction, coronary revascularization, 
angina pectoris, diabetes mellitus, renal dysfunction and 
hypercholesterolemia compared with those who were not 
on beta-blockers (all p-values  0.05). These patients also 
received more often other medications like statins, aspirin 
and corticosteroids (p  0.05). Only two differences were 
found in baseline characteristics between the COPD patients 
who filled out the questionnaire and those who did not 
respond. The non-responding patients were more likely to be 
women and had more frequent history of renal dysfunction 
(p  0.05).
Beta-blockers and COPD
Of the 326 responding COPD patients, 191 (59%) patients 
used beta-blockers at baseline. Of these, 174 (91%) received 
Total patients
with COPD
(n = 1310/3371, 39%)   
COPD patients
alive at follow-up 
(n = 469, 37%)  
Lost to follow-up/
emigrated
(n = 30)    
Response
SF-36 
(n = 326, 70%)   
Beta-blocker 
therapy baseline 
(n = 191, 59%) 
No beta-blocker
therapy baseline 
(n = 135, 41%)  
Beta-blocker use
at follow-up  
(n = 232)  
No beta-blocker
use at follow-up 
(n = 94)  
31 stopped
beta-blocker
72 started
beta-blocker
Figure 1 Patient flow chart.International Journal of COPD 2009:4 180
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Table 1 Baseline characteristics of the study patients
Total  
(n = 326)
Beta-blockersa  
(n = 191)
No beta-blockers  
(n = 135)
p-value
Demographics
  Mean age years (mean (sD)) 66 (10) 68 (9) 64 (11) 0.001
  Male gender 80% 81% 79% 0.67
Type of surgery 0.28
  AAA 50% 53% 44%
  CeA 21% 20% 23%
  LLR 29% 27% 33%
Cardiovascular history
  Myocardial infarction 26% 33% 16% 0.01
  Coronary revascularizationb 23% 28% 15% 0.01
  heart failure 5% 4% 5% 0.67
  Angina pectoris 20% 29% 8% 0.001
  stroke or TIA 25% 25% 25% 0.91
Clinical characteristics
  COPD 0.43
    Mild COPD 54% 54% 53%
    Moderate COPD 37% 36% 40%
    severe COPD 9% 11% 7%
  hypertension 43% 46% 39% 0.26
  Diabetes mellitus 14% 20% 4% 0.001
  hypercholesterolemia 23% 28% 16% 0.01
  Renal dysfunction 19% 23% 12% 0.01
  Body mass index (mean (sD)) 26 (4) 26 (4) 26 (4) 0.81
  Current smoking status 31% 32% 29% 0.56
Medication
  statins 44% 58% 23% 0.001
  Aspirin 49% 56% 39% 0.01
  Bronchodilators 10% 11% 10% 0.98
  Corticosteroids 15% 19% 10% 0.04
aUse at baseline.
bCoronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).
Abbreviations: AAA, abdominal aortic surgery; CeA, carotid endarterectomy; LLR, lower limb arterial reconstruction; TIA, transient ischemic attack; COPD, chronic obstruc-
tive pulmonary disease.
a beta1-selective beta-blocker (ie, bisoprolol, metoprolol 
or atenolol). Of the 191 patients who had received 
beta-blockers at baseline, 31 (16%) had discontinued its 
use (by self-report) at follow-up. All of these patients were 
probed to ascertain the cause for the discontinuation; in no 
case was worsening of pulmonary symptoms noted. The 
distribution of beta-blocker discontinuation between those 
with and without COPD was similar (of the patients who 
had discontinued, 54% did not have COPD and 46% had 
COPD). At baseline 135 COPD patients were not treated 
with beta-blockers, however at follow-up, 72 (53%) of 
these patients had initiated beta-blocker therapy. In total, 
232 (71%) patients were using beta-blockers by the end 
of follow-up. Of these, 204 (88%) used beta1-selective 
beta-blockers (Figure 1).
health-related quality of life
The mean scores on the SF-36 domains according to beta-blocker 
use are presented in Figure 2a. There were no significant 
differences in HRQOL scores between those who were and 
were not taking beta-blockers (p  0.05 for all). Multivariate 
analyses also showed no significant associations between beta-
blockers and the individual domains of the SF-36 in patients 
with COPD: (PF: OR 1.36; 95% CI 0.72–2.61, RP: OR 1.55; 
95% CI 0.78–3.06, BP: OR 1.00; 95% CI 0.52–1.94, GH: OR 
1.27; 95% CI 0.67–2.41, VT: OR 1.29; 95% CI 0.68–2.44, International Journal of COPD 2009:4 181
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SF: OR 1.59; 95% CI 0.87–2.92, RE: OR 1.00; 95% CI 
0.50–1.97, MH: OR 1.15; 95% CI 0.62–2.14) (Figure 3a).
We also evaluated the impact of beta-blocker use at 
follow-up on HRQOL. Again, there were no significant 
differences in mean HRQOL scores between patients who 
were and were not treated with beta-blockers (Figure 2b). 
Beta-blocker therapy at follow-up was not associated with 
impaired health status (PF: OR 1.27; 95% CI 0.72–2.27, RP: 
OR 1.66; 95% CI 0.92–2.98, BP: OR 0.96; 95% CI 0.55–1.69, 
GH: OR 1.50; 95% CI 0.84–2.66, VT: OR 1.22; 95% CI 
0.69–2.14, SF: OR 1.34; 95% CI 0.78–2.29, RE: OR 1.27; 95% 
CI 0.70–2.30, MH: OR 1.57; 95% CI 0.89–2.75) (Figure 3b).
Discussion
In the present study we investigated the relationship between 
beta-blockers and HRQOL in patients with peripheral 
arterial disease and COPD. Our findings indicate that 
beta-blocker therapy does not impair HRQOL in this patient 
population.
These data are similar to a recent review and meta-analysis 
in patients with chronic heart failure, which demonstrated that 
beta-blocker therapy did not impair HRQOL.22 We extend 
these findings by demonstrating a similar relationship in 
COPD patients. The results of our study are also consistent 
with those reported by Mascarenhas and colleagues23 who 
in a cohort of patients with heart failure and COPD, found 
a low withdrawal rate of beta-blockers because of adverse 
effects among those who used these drugs.
Although clinicians are reluctant to prescribe beta-blockers 
to COPD patients for fear of provoking bronchospasm and 
exacerbating lung dysfunction, there is compelling evidence 
to indicate that the benefits (related to cardiovascular 
morbidity and mortality) are likely to outweigh the potential 
risk of adverse events in patients with COPD, especially when 
beta1-selective beta-blockers are used.11–13,24 Previous stud-
ies suggest that beta1-selective beta-blockers can be given 
safely to patients with COPD and do not worsen pulmonary 
function at least in the short-term when used cautiously.5–10 
We have also observed previously that intensified doses 
of beta-blockers were superior to low-dose therapy in 
reducing mortality in patients with COPD, which suggests 
that although it is reasonable to initiate beta-blockers at a 
low dose, if possible, the dose should be titrated upwards 
judiciously and slowly to the therapeutic doses in these 
patients.13
Besides survival and adverse effect, it is also important to 
study the impact of medical treatment on patients’ perspective 
of their health status. To date, HRQOL is often used as a 
secondary endpoint. However, as the focus of COPD man-
agement is to improve HRQOL, it is important that HRQOL 
is not adversely affected by medical therapy that potentially 
prolongs survival, eg, by the treatment with beta-blockers. 
Moreover, knowledge of the patients’ perception of the effect 
of therapy is essential for the physicians’ treatment decisions. 
Importantly, the results of our study indicate that beta-blocker 
therapy does not impair patients’ health status and could be 
used in patients with cardiovascular disease and COPD.
The study has some limitations. First, our study was not 
a randomized controlled trial. As such, although adjustments 
were made for known covariates, there is the possibility of con-
founding by unmeasured variables. In addition, beta-blockers 
were not randomly assigned and therefore subject to confound-
ing by indication. However, propensity analysis was performed 
to adjust as much as possible for this type of bias.25 We did 
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Figure 2 Mean sF-36 scores. A) Mean sF-36 scores of COPD patients with beta-
blocker therapy at baseline; B) Mean sF-36 scores of COPD patients with beta-blocker 
therapy at follow-up.
Abbreviations: PF, physical functioning; RP, role physical; BP, bodily pain; Gh, general 
health;    VT, vitality; sF, social functioning; Re, role emotional; Mh, mental health.International Journal of COPD 2009:4 182
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not have accurate information on the duration of beta-blocker 
exposure and non exposure. A more detailed analysis of the 
relationship between the duration of beta-blocker exposure (or 
non-exposure) at follow-up and HRQOL was therefore not 
possible (eg, a time-dependent covariate analysis). For these 
and other reasons, a randomized controlled trial is needed to 
validate these early findings. Furthermore, during follow-up, 
a number of patients stopped using beta-blockers. It was 
reassuring that patients did not report worsening of their lung 
condition or respiratory symptoms for the discontinuation. 
Nevertheless, a more detailed assessment of long-term pulmo-
nary on and off  beta-blockers, using patient-based symptoms 
questionnaire and lung function testing, would be helpful to 
better understand why certain patients with COPD discontinue 
beta-blocker therapy during follow-up.
In sum, although beta-blockers are often indicated in 
patients with cardiovascular disease, clinicians are reluctant 
to prescribe these drugs to patients with co-existing COPD 
for fear of inducing bronchospasm and worsening their health 
status. The findings of the present study suggest that general 
health status is not materially affected by these drugs. In view 
of their potential life-preserving effects in patients with car-
diovascular disease, these results suggest that beta-blockers 
can in most circumstances be judiciously administered to 
patients with COPD without impairing their HRQOL.
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